IBDEI0E7 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6531,0)
 ;;=C82.30^^30^396^69
 ;;^UTILITY(U,$J,358.3,6531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6531,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,6531,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,6531,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,6532,0)
 ;;=C82.49^^30^396^70
 ;;^UTILITY(U,$J,358.3,6532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6532,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,6532,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,6532,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,6533,0)
 ;;=C82.40^^30^396^71
 ;;^UTILITY(U,$J,358.3,6533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6533,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,6533,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,6533,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,6534,0)
 ;;=C82.99^^30^396^72
 ;;^UTILITY(U,$J,358.3,6534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6534,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,6534,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,6534,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,6535,0)
 ;;=C82.90^^30^396^73
 ;;^UTILITY(U,$J,358.3,6535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6535,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,6535,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,6535,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,6536,0)
 ;;=R59.1^^30^396^58
 ;;^UTILITY(U,$J,358.3,6536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6536,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,6536,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,6536,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,6537,0)
 ;;=C91.40^^30^396^77
 ;;^UTILITY(U,$J,358.3,6537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6537,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,6537,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,6537,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,6538,0)
 ;;=C91.42^^30^396^75
 ;;^UTILITY(U,$J,358.3,6538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6538,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,6538,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,6538,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,6539,0)
 ;;=C91.41^^30^396^76
 ;;^UTILITY(U,$J,358.3,6539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6539,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,6539,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,6539,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,6540,0)
 ;;=D57.01^^30^396^78
 ;;^UTILITY(U,$J,358.3,6540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6540,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,6540,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,6540,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,6541,0)
 ;;=D57.00^^30^396^79
 ;;^UTILITY(U,$J,358.3,6541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6541,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,6541,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,6541,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,6542,0)
 ;;=D57.02^^30^396^80
 ;;^UTILITY(U,$J,358.3,6542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6542,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,6542,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,6542,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,6543,0)
 ;;=D68.32^^30^396^82
 ;;^UTILITY(U,$J,358.3,6543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6543,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,6543,1,4,0)
 ;;=4^D68.32
